Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody.

[1]  Linqi Zhang,et al.  A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus , 2021, Nature Communications.

[2]  P. Brousset,et al.  Epstein–Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features , 2021, Cancers.

[3]  G. Vidarsson,et al.  Augmented antibody-based anti-cancer therapeutics boost neutrophil cytotoxicity. , 2021, The Journal of clinical investigation.

[4]  E. Rowan,et al.  Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview , 2020, Immunologic Research.

[5]  F. Klawonn,et al.  CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease , 2020, Molecular therapy oncolytics.

[6]  M. Bomsel,et al.  Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41 , 2020, Frontiers in Immunology.

[7]  Xiaoqing Yang,et al.  Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth , 2020, Journal for immunotherapy of cancer.

[8]  R. Rochford,et al.  CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells , 2020, Journal of Virology.

[9]  E. Johannsen,et al.  B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection , 2020, PLoS pathogens.

[10]  J. Woof,et al.  IgA: Structure, Function, and Developability , 2019, Antibodies.

[11]  S. Hue,et al.  Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach. , 2019, Pathology.

[12]  A. Rickinson,et al.  The Global Landscape of EBV-Associated Tumors , 2019, Front. Oncol..

[13]  J. Jansen,et al.  Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG , 2019, Front. Immunol..

[14]  M. van Egmond,et al.  IgA and FcαRI: Pathological Roles and Therapeutic Opportunities , 2019, Front. Immunol..

[15]  L. Quintanilla‐Martinez,et al.  Epstein-Barr Virus-Associated T and NK-Cell Lymphoproliferative Diseases , 2019, Front. Pediatr..

[16]  M. Tay,et al.  Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses , 2019, Front. Immunol..

[17]  A. Barzi,et al.  Outlooks on Epstein-Barr virus associated gastric cancer. , 2018, Cancer treatment reviews.

[18]  M. Gray,et al.  An Antibody Targeting the Fusion Machinery Neutralizes Dual‐Tropic Infection and Defines a Site of Vulnerability on Epstein‐Barr Virus , 2018, Immunity.

[19]  M. Bomsel,et al.  IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis , 2018, Front. Immunol..

[20]  Lijun Xu,et al.  CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy , 2018, Oncoimmunology.

[21]  S. Peh,et al.  Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment , 2017, Journal of pathogens.

[22]  L. Cavacini,et al.  Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition , 2016, Journal of immunology research.

[23]  T. Jardetzky,et al.  Structural and Mechanistic Insights into the Tropism of Epstein-Barr Virus , 2016, Molecules and cells.

[24]  Å. Helland,et al.  Rituximab efficiently depletes B cells in lung tumors and normal lung tissue , 2016, F1000Research.

[25]  U. Baxa,et al.  Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site , 2015, Cell.

[26]  M. Rowe,et al.  Epstein Barr virus entry; kissing and conjugation. , 2014, Current opinion in virology.

[27]  H. Einsele,et al.  Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  D. Teachey,et al.  Treatment of Epstein Barr virus‐induced haemophagocytic lymphohistiocytosis with rituximab‐containing chemo‐immunotherapeutic regimens , 2013, British journal of haematology.

[29]  H. Heslop,et al.  T-cell therapy in the treatment of post-transplant lymphoproliferative disease , 2012, Nature Reviews Clinical Oncology.

[30]  H. Varmus,et al.  Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention , 2011, Science Translational Medicine.

[31]  M. Pender.  The Essential Role of Epstein-Barr Virus in the Pathogenesis of Multiple Sclerosis , 2011, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[32]  A. Barrett,et al.  Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  P. Ljungman,et al.  Targeted monitoring of patients at high risk of post‐transplant lymphoproliferative disease by quantitative Epstein–Barr virus polymerase chain reaction , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[34]  L. Cavacini,et al.  A Bispecific Antibody Composed of a Nonneutralizing Antibody to the gp41 Immunodominant Region and an Anti-CD89 Antibody Directs Broad Human Immunodeficiency Virus Destruction by Neutrophils , 2008, Journal of Virology.

[35]  M. Moutschen,et al.  Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. , 2007, The Journal of infectious diseases.

[36]  G. Mieli-Vergani,et al.  A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo. , 2006, The Journal of infectious diseases.

[37]  M. Khyatti,et al.  Establishment and characterization of Epstein‐Barr virus gp350‐expressing transfected human lymphoid (Raji) cell clones , 1991, International journal of cancer.

[38]  H. Shim,et al.  Construction of Rabbit Immune Antibody Libraries. , 2018, Methods in molecular biology.

[39]  R. Monteiro,et al.  IgA Fc receptors. , 2003, Annual review of immunology.

[40]  K. Shen,et al.  Open Access Research Characterization of Variants in the Promoter of Bzlf1 Gene of Ebv in Nonmalignant Ebv-associated Diseases in Chinese Children , 2022 .